No Data
Kissei Pharmaceutical Reports Strong Sales Growth Amid Higher R&D Costs
Kissei Pharmaceutical: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending 2025/3
Kawasaki Kisen Kaisha and others announced a share buyback on November 5th.
The stocks that announced the establishment of a self-share purchase framework on Tuesday, November 5th, are as follows: <9107> Kawasaki Kisen 36 million shares (5.3%) 90 billion yen (24/11/6-25/2/28) <9064> Yamato Holdings 39 million shares (11.4%) 50 billion yen (24/11/18-25/9/30) <2871> Nichirei 3 million shares (2.4%) 10 billion yen (24/11/6-25/2/28) <6908> Iriso Electronics 2 million shares (8.9%) 6 billion yen (24/11/6-25
nintendo co ltd, downward revision on 25/3 operating profit 360 billion yen←400 billion yen
Nintendo Co Ltd <7974> announced a revision of its financial estimates for the fiscal year ending March 2025. Revenue was revised downward from 1.35 trillion yen to 1.28 trillion yen, and operating profit was lowered from 400 billion yen to 360 billion yen. The main game console, Nintendo Switch, and software sales are declining. The sales plan for the Switch this fiscal year is reduced by 20% to 12.5 million units, and the number of Switch software sales is reduced by 20% to 1.06 billion units, each with a downward revision of 1 million units and 50 million units from the previous estimates, respectively. [Positive review]
Kissei Pharmaceutical Plans Share Buyback and Cancellation
Kissei Pharmaceutical: Consolidated Financial Results for the 2nd Quarter (Interim Period) for the Fiscal Year Ending March 31, 2025 [Japanese GAAP] (Consolidated)
No Data
No Data